You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEszopiclone
Accession NumberDB00402  (APRD00431)
TypeSmall Molecule
GroupsApproved
DescriptionEszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic agent (viz., a sedative) used as a treatment for insomnia. Eszopiclone is the active stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrones. Its main selling point is that it is approved by the U.S. Food and Drug Administration for long-term use, unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia.
Structure
Thumb
Synonyms
(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate
(+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methylpiperazine-1-carboxylate
(+)-Zopiclone
(S)-6-(5-Chloro-2-pyridinyl)- 7-oxo- 6,7-dihydro- 5H-pyrrolo[3,4-b]pyrazin-5-yl- 4-methyl- 1-piperazinecarboxylate
(S)-Zopiclone
1-Piperazinecarobxylic acid,4-methyl-,(5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester
Esopiclone
Estorra
Eszopiclone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LunestaTablet, coated3 mg/1OralUnit Dose Services2005-04-04Not applicableUs
LunestaTablet2 mgOralSunovion Pharmaceuticals Canada IncNot applicableNot applicableCanada
LunestaTablet, coated2 mg/1OralRebel Distributors Corp2009-01-01Not applicableUs
LunestaTablet, coated2 mg/1OralSt Marys Medical Park Pharmacy2005-04-04Not applicableUs
LunestaTablet, coated2 mg/1OralSunovion Pharmaceuticals Inc.2005-04-04Not applicableUs
LunestaTablet, coated2 mg/1OralA S Medication Solutions Llc2005-04-04Not applicableUs
LunestaTablet, coated2 mg/1OralDispensing Solutions, Inc.2005-04-04Not applicableUs
LunestaTablet, coated2 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-18Not applicableUs
LunestaTablet, coated3 mg/1OralH.J. Harkins Company, Inc.2005-04-04Not applicableUs
LunestaTablet3 mgOralSunovion Pharmaceuticals Canada IncNot applicableNot applicableCanada
LunestaTablet, coated3 mg/1OralRebel Distributors Corp2009-01-01Not applicableUs
LunestaTablet, coated3 mg/1OralSt Marys Medical Park Pharmacy2005-04-04Not applicableUs
LunestaTablet, coated3 mg/1OralSunovion Pharmaceuticals Inc.2005-04-04Not applicableUs
LunestaTablet, coated2 mg/1OralPhysicians Total Care, Inc.2005-04-27Not applicableUs
LunestaTablet, coated3 mg/1OralDispensing Solutions, Inc.2005-04-04Not applicableUs
LunestaTablet, coated3 mg/1OralA S Medication Solutions Llc2005-04-04Not applicableUs
LunestaTablet, coated3 mg/1OralPd Rx Pharmaceuticals, Inc.2005-04-04Not applicableUs
LunestaTablet, coated2 mg/1OralH.J. Harkins Company, Inc.2005-04-04Not applicableUs
LunestaTablet, coated3 mg/1Oralbryant ranch prepack2005-04-04Not applicableUs
LunestaTablet, coated3 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-07-18Not applicableUs
LunestaTablet, coated3 mg/1OralPhysicians Total Care, Inc.2005-08-24Not applicableUs
LunestaTablet, coated2 mg/1OralA S Medication Solutions Llc2005-04-04Not applicableUs
LunestaTablet1 mgOralSunovion Pharmaceuticals Canada IncNot applicableNot applicableCanada
LunestaTablet, coated1 mg/1OralSunovion Pharmaceuticals Inc.2005-04-04Not applicableUs
LunestaTablet, coated3 mg/1OralA S Medication Solutions Llc2005-04-04Not applicableUs
LunestaTablet, coated2 mg/1Oralbryant ranch prepack2005-04-04Not applicableUs
LunestaTablet, coated1 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-07-18Not applicableUs
LunestaTablet, coated1 mg/1OralPhysicians Total Care, Inc.2006-09-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EszopicloneTablet, film coated2 mg/1OralPreferred Pharmaceuticals, Inc.2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1Oralbryant ranch prepack2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralOrchid Pharma Inc2014-09-25Not applicableUs
EszopicloneTablet, film coated3 mg/1OralUnit Dose Services2014-04-14Not applicableUs
EszopicloneTablet, film coated2 mg/1Oralbryant ranch prepack2014-04-15Not applicableUs
EszopicloneTablet1 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralAurobindo Pharma Limited2016-09-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralPreferred Pharmaceuticals Inc.2015-11-20Not applicableUs
EszopicloneTablet, film coated1 mg/1OralDIRECT RX2015-01-01Not applicableUs
EszopicloneTablet, film coated1 mg/1OralTeva Pharmaceuticals USA Inc2014-04-14Not applicableUs
EszopicloneTablet, film coated1 mg/1OralSun Pharma Global FZE2014-04-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralSt. Mary's Medical Park Pharmacy2016-04-14Not applicableUs
EszopicloneTablet, film coated3 mg/1OralA S Medication Solutions Llc2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralAphena Pharma Solutions Tennessee, Llc2016-01-19Not applicableUs
EszopicloneTablet, film coated1 mg/1OralA S Medication Solutions2014-04-14Not applicableUs
EszopicloneTablet, film coated1 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-04-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralAv Kare, Inc.2014-05-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralA S Medication Solutions Llc2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralMylan Pharmaceuticals Inc.2013-03-26Not applicableUs
EszopicloneTablet, film coated3 mg/1OralUnit Dose Services2014-09-25Not applicableUs
EszopicloneTablet, film coated1 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-15Not applicableUs
EszopicloneTablet2 mg/1OralProficient Rx LP2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralMacleods Pharmaceuticals Limited2014-04-25Not applicableUs
EszopicloneTablet, film coated3 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-05-15Not applicableUs
EszopicloneTablet2 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralA S Medication Solutions2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralLupin Pharmaceuticals, Inc.2014-04-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralOrchid Pharma Inc2014-09-25Not applicableUs
EszopicloneTablet, film coated2 mg/1OralMylan Institutional Inc.2014-11-11Not applicableUs
EszopicloneTablet1 mg/1OralWest Ward Pharmaceuticals Corp.2014-04-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralAurobindo Pharma Limited2016-09-15Not applicableUs
EszopicloneTablet3 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-13Not applicableUs
EszopicloneTablet, film coated1 mg/1OralDIRECT RX2015-01-01Not applicableUs
EszopicloneTablet, film coated2 mg/1OralTeva Pharmaceuticals USA Inc2014-04-14Not applicableUs
EszopicloneTablet, film coated2 mg/1OralSun Pharma Global FZE2014-04-15Not applicableUs
EszopicloneTablet, coated3 mg/1OralDr. Reddy's Laboratories Limited2014-04-15Not applicableUs
EszopicloneTablet3 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralGolden State Medical Supply, Inc.2016-01-19Not applicableUs
EszopicloneTablet, film coated2 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-04-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralMedsource Pharmaceuticals2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralUnit Dose Services2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralMylan Pharmaceuticals Inc.2013-03-26Not applicableUs
EszopicloneTablet, coated2 mg/1OralUnit Dose Services2014-04-15Not applicableUs
EszopicloneTablet1 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-20Not applicableUs
EszopicloneTablet, film coated1 mg/1OralProficient Rx LP2014-09-25Not applicableUs
EszopicloneTablet, film coated3 mg/1OralMacleods Pharmaceuticals Limited2014-04-25Not applicableUs
EszopicloneTablet, film coated3 mg/1OralMylan Institutional Inc.2014-11-11Not applicableUs
EszopicloneTablet, film coated2 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-05-15Not applicableUs
EszopicloneTablet3 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-04-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralDIRECT RX2015-12-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralLupin Pharmaceuticals, Inc.2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralAv Kare, Inc.2014-05-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralSun Pharma Global FZE2014-04-15Not applicableUs
EszopicloneTablet2 mg/1OralWest Ward Pharmaceuticals Corp.2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralA S Medication Solutions2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-21Not applicableUs
EszopicloneTablet, film coated1 mg/1OralDIRECT RX2015-12-01Not applicableUs
EszopicloneTablet, film coated3 mg/1OralTeva Pharmaceuticals USA Inc2014-04-14Not applicableUs
EszopicloneTablet, film coated3 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralMedsource Pharmaceuticals2014-04-15Not applicableUs
EszopicloneTablet, coated2 mg/1OralDr. Reddy's Laboratories Limited2014-04-15Not applicableUs
EszopicloneTablet3 mg/1OralProficient Rx LP2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralGolden State Medical Supply, Inc.2016-01-19Not applicableUs
EszopicloneTablet, film coated3 mg/1OralPreferred Pharmaceuticals Inc.2015-08-18Not applicableUs
EszopicloneTablet, film coated3 mg/1Oralbryant ranch prepack2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralOrchid Pharma Inc2014-09-25Not applicableUs
EszopicloneTablet, film coated2 mg/1OralUnit Dose Services2014-04-14Not applicableUs
EszopicloneTablet, film coated3 mg/1OralMylan Pharmaceuticals Inc.2013-03-26Not applicableUs
EszopicloneTablet, film coated3 mg/1OralDIRECT RX2014-01-01Not applicableUs
EszopicloneTablet, film coated2 mg/1OralA S Medication Solutions Llc2014-04-15Not applicableUs
EszopicloneTablet, film coated3 mg/1OralAphena Pharma Solutions Tennessee, Llc2016-01-19Not applicableUs
EszopicloneTablet, film coated3 mg/1OralProficient Rx LP2014-09-25Not applicableUs
EszopicloneTablet, film coated3 mg/1OralLupin Pharmaceuticals, Inc.2014-04-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralAv Kare, Inc.2014-05-15Not applicableUs
EszopicloneTablet, film coated2 mg/1OralA S Medication Solutions Llc2014-04-15Not applicableUs
EszopicloneTablet3 mg/1OralWest Ward Pharmaceuticals Corp.2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralA S Medication Solutions2014-04-14Not applicableUs
EszopicloneTablet, film coated1 mg/1OralPreferred Pharmaceuticals, Inc.2015-04-15Not applicableUs
EszopicloneTablet1 mg/1OralProficient Rx LP2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralMacleods Pharmaceuticals Limited2014-04-25Not applicableUs
EszopicloneTablet, film coated3 mg/1OralGolden State Medical Supply, Inc.2016-01-19Not applicableUs
EszopicloneTablet, film coated2 mg/1OralPreferred Pharmaceuticals Inc.2015-10-06Not applicableUs
EszopicloneTablet, film coated1 mg/1OralMedsource Pharmaceuticals2014-04-15Not applicableUs
EszopicloneTablet, coated1 mg/1OralDr. Reddy's Laboratories Limited2014-04-15Not applicableUs
EszopicloneTablet, film coated1 mg/1OralAurobindo Pharma Limited2016-09-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DorplenLKM
EsleepOpsonin
EszopSilesia
FulniteSun
InductalRoemmers
IsoklonTecnoquimicas
NirvanSaval
NopticAndromaco
PlessirMedipharm
SanilentSanitas
SleepilAristopharma
SonoAcme
ValnocDrugtech
Wen FeiTasly
ZopiloneIncepta
ZopinonChile
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIUZX80K71OE
CAS number138729-47-2
WeightAverage: 388.808
Monoisotopic: 388.105066147
Chemical FormulaC17H17ClN6O3
InChI KeyGBBSUAFBMRNDJC-INIZCTEOSA-N
InChI
InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
IUPAC Name
(5S)-6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate
SMILES
CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1
Pharmacology
IndicationFor the treatment of insomnia
Structured Indications
PharmacodynamicsEszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Eszopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.
Mechanism of actionThe mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinunknown
agonist
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinunknown
agonist
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinunknown
agonist
HumanP31644 details
Translocator proteinProteinyes
agonist
HumanP30536 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionRapidly absorbed following oral administration
Volume of distributionNot Available
Protein binding52-59%
Metabolism

Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation.

SubstrateEnzymesProduct
Eszopiclone
Zopiclone N-oxideDetails
Eszopiclone
nopiclone N-oxideDetails
Eszopiclone
zopiclone-N-oxideDetails
Eszopiclone
N-desmethylzopicloneDetails
Eszopiclone
Carbon dioxideDetails
Route of eliminationUp to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites.
Half life6 hours
ClearanceNot Available
ToxicitySide effects include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste depending on doses.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Eszopiclone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alprazolam.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Eszopiclone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amperozide.Experimental
AprepitantThe serum concentration of Eszopiclone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Asenapine.Approved
AtazanavirThe metabolism of Eszopiclone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Eszopiclone can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Azaperone.Vet Approved
AzelastineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Eszopiclone can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Eszopiclone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Eszopiclone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Eszopiclone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Eszopiclone.Approved, Investigational
BuprenorphineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Eszopiclone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butorphanol.Approved, Illicit, Vet Approved
CapecitabineThe metabolism of Eszopiclone can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Eszopiclone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Eszopiclone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Eszopiclone can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Eszopiclone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CinchocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Citalopram.Approved
ClarithromycinThe metabolism of Eszopiclone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Eszopiclone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clonidine.Approved
ClopidogrelThe metabolism of Eszopiclone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Eszopiclone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Eszopiclone.Approved
CobicistatThe metabolism of Eszopiclone can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Eszopiclone.Approved, Illicit
ConivaptanThe serum concentration of Eszopiclone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Eszopiclone can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Eszopiclone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Eszopiclone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Eszopiclone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Eszopiclone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Eszopiclone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Eszopiclone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Eszopiclone can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Eszopiclone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diazepam.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Eszopiclone can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Eszopiclone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Doxepin.Approved
DoxycyclineThe metabolism of Eszopiclone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Eszopiclone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Illicit
DronedaroneThe metabolism of Eszopiclone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Eszopiclone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Eszopiclone can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Eszopiclone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Eszopiclone can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Eszopiclone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Eszopiclone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Estazolam.Approved, Illicit
EthanolEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Eszopiclone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Eszopiclone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Eszopiclone can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Felbamate.Approved
FelodipineThe metabolism of Eszopiclone can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flibanserin.Approved
FloxuridineThe metabolism of Eszopiclone can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Eszopiclone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fludiazepam.Approved, Illicit
FlumazenilFlumazenil may decrease the sedative activities of Eszopiclone.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Eszopiclone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Eszopiclone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Eszopiclone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Eszopiclone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Eszopiclone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Eszopiclone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Eszopiclone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Eszopiclone can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Hexobarbital.Approved
HydrocodoneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Eszopiclone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
IdelalisibThe serum concentration of Eszopiclone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Iloperidone.Approved
ImatinibThe metabolism of Eszopiclone can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Eszopiclone can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Eszopiclone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Eszopiclone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Isoflurane.Approved, Vet Approved
IsradipineThe metabolism of Eszopiclone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Eszopiclone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Eszopiclone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Eszopiclone can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Eszopiclone can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Eszopiclone can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Eszopiclone.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lofentanil.Illicit
LopinavirThe metabolism of Eszopiclone can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Eszopiclone.Approved
LosartanThe metabolism of Eszopiclone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Eszopiclone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Eszopiclone is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Eszopiclone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Eszopiclone can be increased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Eszopiclone.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Eszopiclone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methohexital.Approved
MethotrimeprazineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methylphenobarbital.Approved
MetyrosineEszopiclone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Eszopiclone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Investigational
MirtazapineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Eszopiclone can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Eszopiclone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Eszopiclone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved, Investigational
NafcillinThe serum concentration of Eszopiclone can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Eszopiclone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Eszopiclone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Eszopiclone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Eszopiclone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Eszopiclone can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Eszopiclone can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Eszopiclone.Approved, Investigational
OlaparibThe metabolism of Eszopiclone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Eszopiclone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Opium.Approved, Illicit
OrphenadrineEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Eszopiclone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Eszopiclone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paliperidone.Approved
ParaldehydeEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Eszopiclone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
PerazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Eszopiclone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Eszopiclone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pimozide.Approved
PioglitazoneThe metabolism of Eszopiclone can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Eszopiclone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleEszopiclone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Eszopiclone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prilocaine.Approved
PrimidoneThe metabolism of Eszopiclone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Eszopiclone is combined with PSD502.Investigational
PyrimethamineThe metabolism of Eszopiclone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quetiapine.Approved
QuinineThe metabolism of Eszopiclone can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Eszopiclone can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Eszopiclone can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Eszopiclone.Approved
RifabutinThe metabolism of Eszopiclone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Eszopiclone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Eszopiclone can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ritanserin.Investigational
RitonavirThe metabolism of Eszopiclone can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Romifidine.Vet Approved
RopiniroleEszopiclone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Eszopiclone.Approved
RosiglitazoneThe metabolism of Eszopiclone can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineEszopiclone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Eszopiclone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Eszopiclone is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Eszopiclone is combined with Sage 547.Investigational
SaquinavirThe metabolism of Eszopiclone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Eszopiclone can be increased when combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Eszopiclone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Eszopiclone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Eszopiclone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SorafenibThe metabolism of Eszopiclone can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Eszopiclone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Eszopiclone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Eszopiclone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Eszopiclone can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Eszopiclone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Eszopiclone.Approved
SuvorexantEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe metabolism of Eszopiclone can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Eszopiclone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Eszopiclone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Eszopiclone.Approved
TeriflunomideThe metabolism of Eszopiclone can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrodotoxin.Investigational
ThalidomideEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiapride.Investigational
TicagrelorThe metabolism of Eszopiclone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Eszopiclone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Eszopiclone can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Eszopiclone can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Eszopiclone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe metabolism of Eszopiclone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Eszopiclone is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Eszopiclone.Approved, Investigational
ValsartanThe metabolism of Eszopiclone can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Eszopiclone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Eszopiclone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Eszopiclone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Xylazine.Vet Approved
ZafirlukastThe metabolism of Eszopiclone can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Eszopiclone can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zolazepam.Vet Approved
ZolpidemEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Marioara MENDELOVICI, Anita LIBERMAN, Alex MAINFELD, Nina FINKELSTEIN, “METHODS FOR PREPARING ESZOPICLONE CRYSTALLINE FORM A, SUBSTANTIALLY PURE ESZOPICLONE AND OPTICALLY ENRICHED ESZOPICLONE.” U.S. Patent US20070270590, issued November 22, 2007.

US20070270590
General ReferencesNot Available
External Links
ATC CodesN05CF04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (252 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9382
Caco-2 permeable+0.5805
P-glycoprotein substrateSubstrate0.6917
P-glycoprotein inhibitor IInhibitor0.6381
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.6785
CYP450 2C9 substrateNon-substrate0.7158
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.6775
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.689
Ames testAMES toxic0.5332
CarcinogenicityNon-carcinogens0.9174
BiodegradationNot ready biodegradable0.9941
Rat acute toxicity2.6411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7838
hERG inhibition (predictor II)Non-inhibitor0.5688
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sepracor inc
  • Sepracor Inc.
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg/1
TabletOral2 mg/1
TabletOral3 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral3 mg/1
TabletOral1 mg
TabletOral2 mg
TabletOral3 mg
Tablet, coatedOral1 mg/1
Tablet, coatedOral2 mg/1
Tablet, coatedOral3 mg/1
Prices
Unit descriptionCostUnit
Lunesta 2 mg tablet8.08USD tablet
Lunesta 3 mg tablet7.28USD tablet
Lunesta 1 mg tablet7.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6319926 No1995-01-162012-01-16Us
US6444673 No1994-02-142014-02-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityvery slightly solubleNot Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.885 mg/mLALOGPS
logP0.97ALOGPS
logP0.81ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.04ChemAxon
pKa (Strongest Basic)6.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area91.76 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.89 m3·mol-1ChemAxon
Polarizability37.67 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclopyrrolones. These are compounds belonging to a family of pyridin-2-ylpyrrole based chemicals. The pyrrole is usually fused to a benzene, pyrimidine, or dithiin.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyrrolopyrazines
Sub ClassCyclopyrrolones
Direct ParentCyclopyrrolones
Alternative Parents
Substituents
  • Cyclopyrrolone
  • Piperazine-1-carboxylic acid
  • N-alkylpiperazine
  • N-methylpiperazine
  • Aminopyridine
  • Imidolactam
  • Pyridine
  • Pyrazine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010 Nov;24(11):1601-12. doi: 10.1177/0269881109106927. Epub 2009 Nov 26. [PubMed:19942638 ]
  2. Hanson SM, Morlock EV, Satyshur KA, Czajkowski C: Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different. J Med Chem. 2008 Nov 27;51(22):7243-52. doi: 10.1021/jm800889m. [PubMed:18973287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Becker PM, Sattar M: Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol. 2009 Sep;11(5):349-57. [PubMed:19744401 ]
  4. Jufe GS: [New hypnotics: perspectives from sleep physiology]. Vertex. 2007 Jul-Aug;18(74):294-9. [PubMed:18265473 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54. [PubMed:15039299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23